Table 1 Survey responses.
From: Development of an evidence-based evaluation framework for digital health software products
Responses | Adopters (n = 45) | Developers (n = 32) | Regulators, Investors, Industry associations (n = 16) |
|---|---|---|---|
Question: Which of these criteria is most important to you when evaluating a new DHSP? | |||
Clinical outcomes clearly defined | 27% | 24% | 26% |
Appropriate privacy/security measures | 23% | 23% | 10% |
Ease of use | 18% | 23% | 16% |
Product integrates into workflows | 16% | 14% | 13% |
Inclusively designed, where appropriate | 5% | 13% | 10% |
Overall return on investment | 8% | 3% | 19% |
Other | 3% | 0% | 6% |
Question: What value would an evaluation framework for DHSPs bring to healthcare? | |||
Easier to tell which products are fit for my purpose | 24% | 20% | 25% |
Clear picture of costs, reimbursement options | 18% | 10% | 14% |
Faster time to adoption of new products | 17% | 19% | 18% |
Better products in the market | 16% | 17% | 14% |
Increased transparency for decisions made during product development process | 15% | 20% | 18% |
More innovative products in the market | 10% | 14% | 11% |
No value | 0% | 0% | 0% |
Question: Which domain is most important when evaluating a new DHSP? | |||
Evidence | 64% | 43% | 64% |
Usability | 25% | 33% | 18% |
Privacy & security | 11% | 24% | 18% |
Question: Which context area is most important when evaluating a new DHSP? | |||
Outcomes | 67% | 62% | 64% |
Equity and inclusion | 19% | 19% | 36% |
Workflow integration | 14% | 19% | 0% |
